Collaborative expansion ProImmune is actively pursuing partnerships with premier research institutions (example UTMB GNL) to develop tools for studying high-consequence infectious diseases, signaling opportunities for joint development, contract research, and access to their immune reagents and platforms.

Immunology platform With an integrated antigen characterization platform and capabilities in ELISpot and flow cytometry, ProImmune offers a comprehensive suite that can enhance preclinical and clinical immunology programs for clients seeking advanced immune monitoring and characterization.

Growing footprint Operating with 51-200 employees and revenue in the low-to-mid single digits, ProImmune presents a scalable partner for mid-market biotech and academic collaborations, potential channel or services expansion without requiring large enterprise-level commitments.

Emerging disease focus Recent news emphasizes development of tools for high-consequence and endemic infectious diseases, creating sales angles around infectious disease research outsourcing, reagent access, and specialized assay development.

Digital and omni-channel Utilizing AWS, e-commerce platforms (Shopify/WooCommerce), and engagement tools (WhatsApp Business, iCIMS), ProImmune demonstrates a modern tech stack suitable for streamlined procurement, customer support, and scalable online sales and service delivery.